Table 3 The baseline characteristics of the healthy control subjects and the enrolled IPF patients

Sex, male, n (%)

16 (76)

32 (78)

Age, median (IQR)

69 (66–73)

72 (68–80)

Surgical lung biopsy undergo, n (%)

N.A.

15 (36)

Baseline % predicted VC, median (IQR)

109 (100–120)

81 (67–93)

Emphysematous lesion detected by CT, n (%) ^a

N.A.

4 (10)

KL-6

N.A.

739 (557–1320)

SP-D

N.A.

207 (142–303)

LDH

N.A.

208 (183–247)

Yes, n (%)

17 (80)

34 (82)

Therapy, n (%)

N.A.

No treatment

N.A.

24 (58)

Pirfenidone

N.A.

10 (24)

Prednisolone

N.A.

8 (19)

Cyclosporine A

N.A.

2 (4)